Pasotuxizumab Biosimilar – Anti-CD3E, FOLH1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1353; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Pasotuxizumab Biosimilar, also known as Anti-CD3E, FOLH1 mAb, is a monoclonal antibody that has been developed as a biosimilar to the therapeutic antibody, Pasotuxizumab, which targets the CD3E and FOLH1 proteins. This biosimilar is a promising candidate for the treatment of various diseases, and its structure, activity, and potential applications will be discussed in this article.
Pasotuxizumab Biosimilar is a fully human monoclonal antibody that is composed of two heavy chains and two light chains. It has a molecular weight of approximately 150 kDa and is produced using recombinant DNA technology. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to the target proteins, CD3E and FOLH1, while the Fc region is involved in immune effector functions.
Pasotuxizumab Biosimilar binds specifically to the CD3E and FOLH1 proteins, which are expressed on the surface of immune cells and cancer cells, respectively. This binding leads to the activation of immune cells, such as T cells, and the inhibition of cancer cell growth. Pasotuxizumab Biosimilar has been shown to induce apoptosis (programmed cell death) in cancer cells, as well as activate immune cells to attack and destroy cancer cells.
cancer activity, Pasotuxizumab Biosimilar has also been found to have immunomodulatory effects. It can regulate the immune response by promoting the production of anti-inflammatory cytokines and inhibiting the production of pro-inflammatory cytokines. This makes it a potential treatment option for autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.
Pasotuxizumab Biosimilar is currently being investigated as a potential treatment for various types of cancer, including prostate cancer, ovarian cancer, and colorectal cancer. It has shown promising results in preclinical studies and is now being evaluated in clinical trials. The biosimilar is being tested as a monotherapy and in combination with other anti- cancer drugs, and early results have shown good efficacy and safety profiles.
Apart from its potential in cancer treatment, Pasotuxizumab Biosimilar also has potential applications in the treatment of autoimmune diseases. Its immunomodulatory effects make it a promising candidate for the treatment of diseases where the immune system is overactive, such as rheumatoid arthritis and multiple sclerosis. Clinical trials for these indications are also underway.
In conclusion, Pasotuxizumab Biosimilar is a fully human monoclonal antibody that targets the CD3E and FOLH1 proteins. Its structure, activity, and potential applications make it a promising candidate for the treatment of various diseases, especially cancer and autoimmune diseases. Further research and clinical trials are needed to fully understand the potential of this biosimilar and its role in improving patient outcomes.
ProteoGenix catalogue number PX-TA1353. For research use only.
Target: Pasotuxizumab Biosimilar – Anti-CD3E, FOLH1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Pasotuxizumab Biosimilar – Anti-CD3E, FOLH1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
